PAVmed | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 5 K

Revenue: As of FY2025 Q3, the actual value is USD 5 K, missing the estimate of USD 12.5 K.

EPS: As of FY2025 Q3, the actual value is USD -0.29.

EBIT: As of FY2025 Q3, the actual value is USD -4.846 M.

Financial Results

Operating Expenses

• For the three months ended September 30, 2025, operating expenses were approximately $4.8 million, including stock-based compensation expenses of $0.4 million.

Net Loss

• GAAP net loss attributable to common stockholders was approximately $6.3 million, or - $0.29 per common share on a diluted basis.

Non-GAAP Adjusted Loss

• The non-GAAP adjusted loss was approximately $0.4 million or - $0.02 per common share.

Cash and Cash Equivalents

• PAVmed had cash and cash equivalents of $3.1 million as of September 30, 2025, compared to $1.2 million as of December 31, 2024.

Unique Metrics

EsoGuard Revenue

• Lucid Diagnostics recognized $1.2 million in revenue from the EsoGuard Esophageal DNA Test for the third quarter of 2025 and processed 2,841 EsoGuard tests.

Outlook / Guidance

• PAVmed expects to benefit from the success of its subsidiaries as they advance toward major milestones, including Veris’s FDA submission for its implantable physiological monitor and Lucid’s approach to transformative Medicare coverage for EsoGuard.